Fostamatinib – IgAN


Oral SYK Inhibitor for IgA Nephropathy:

  • A major function of the kidneys is to eliminate and dispose of waste products by filtering the blood and producing urine.
  • IgA Nephropathy (IgAN) is a chronic autoimmune disease associated with inflammation in the kidneys that diminishes their ability to filter blood.
  • IgAN is the most common primary glomerular disease. There are an estimated 82,500 - 165,000 cases in the US, with a higher prevalence in Asia.
  • Outside of angiotensin blockade (primarily for blood-pressure control), there are no disease-targeted therapies for IgAN.
  • Pre-clinical data show that fostamatinib, Rigel's oral SYK inhibitor, decreases SYK activation in the kidney, resulting in the reversal of the inflammation in the glomeruli and improvement in kidney function.
  • Rigel announced results of the first cohort (100mg BID, n=26; placebo n=12) of a Phase 2 study of fostamatinib in IgAN in January 2017. Rigel expects that the second cohort, evaluating a higher dose of fostamatinib (150mg BID), will finish enrollment in 2017 with full results in 2018.

Clinical Trials:

Phase 2 - IgA Nephropathy

MOA Animation: